NDC 22607-679-02 - Piperacillin and Tazobactam
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 22607-679
- Requested NDC
- 22607-679-02
- Package NDCs from labels
- 22607-679-02, 22607-679-01
- Manufacturer
- Mitim S.r.l. | Wockhardt Limited
- Effective date
- 2017-03-29
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Piperacillin and Tazobactam - Mitim S.r.l. | Wockhardt Limited | Mitim S.r.l. | Wockhardt Limited | 2017-03-29 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 22607-679-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9cf-fd6d-f424-e053-dadaa90a57ce | These highlights do not include all the information needed to use PIPERACILLIN AND TAZOBACTAM FOR INJECTION safely and effectively. See full prescribing information for PIPERACILLIN AND TAZOBACTAM FOR INJECTION. PIPERACILLIN and TAZOBACTAM for Injection, for intravenous use Initial U.S. approval: 1993 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | fc4d1e35-23eb-4654-8691-ae5bfd50a48a | 2024-10-16 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | e53ebafc-3afa-4a1e-9313-fecd1c1c5d7c | 2024-10-16 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | ba87ade3-4d41-40c0-9f6a-27e121a4136d | 2024-10-16 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | 2cfa6723-175b-4c4d-8212-266844b07610 | 2024-10-16 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | c78e0931-ec79-58e5-8658-7fe692dc3b8b | 2024-10-16 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Apotex Corp. | c18109cf-d5db-4cc1-83da-537c8ab0e05c | 2024-10-14 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Shandong Anxin Pharmaceutical Co., Ltd. | f817b9be-b12b-48ac-8e4e-57ef6812eb32 | 2024-10-14 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| piperacillin and tazobactam | PIPERACILLIN AND TAZOBACTAM | Armas Pharmaceuticals Inc. | 24d9b4f1-109c-4db4-8a99-03afff045b47 | 2024-09-27 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| piperacillin and tazobactam | PIPERACILLIN AND TAZOBACTAM | Armas Pharmaceuticals Inc. | bbd1e6ae-e19a-4572-a0ec-e78c8aa31d2a | 2024-09-27 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Eugia US LLC | 80f4bdb8-131e-4485-b7a2-accd596d4cde | 2024-09-04 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin, Tazobactam | PIPERACILLIN SODIUM, TAZOBACTAM SODIUM | Sagent Pharmaceuticals | 83f4adcd-893c-4e9e-8f2b-e06299dcf34d | 2024-08-31 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Sandoz Inc | b1cb1314-d3e0-4b44-a1df-de14c32e8cc6 | 2024-08-23 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Hospira, Inc | 5e8bbfcd-3618-43ed-a158-9d524426fdc5 | 2024-08-23 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Zosyn in Galaxy Containers | TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. | 8ab9d90d-2f7f-4599-a44f-3d0a8f8ab623 | 2023-03-15 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | dc8208ea-a632-4291-a90b-2eba9a33bb40 | 2022-10-27 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | b9bd733c-1176-42cb-b318-1223b7e48dcb | 2021-05-19 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | 1eb40c84-0cb3-4648-a39f-f4ebc4dbcb16 | 2021-04-02 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| 68e829fe-50ce-4640-908b-2ec4b6ffbe9a | 9fbff25f-374d-4381-b288-d281bcd7cfcc | 2017-03-29 | Warnings, Adverse reactions | 68e829fe-50ce-4640-908b-2ec4b6ffbe9a 9fbff25f-374d-4381-b288-d281bcd7cfcc |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.